Logo for ICAN - International Collaborative Asthma Network

The International Collaborative Asthma Network invites you to submit an abstract on an innovative, collaborative idea for studying and managing asthma.

Abstract Submission is open from January 15, 2022-February 6, 2022.

This focus of this meeting will be to promote innovation and to strengthen international collaborations on asthma in general and severe asthma in particular.  There is a heightened need in the space beyond the T2 asthma phenotype. This meeting will be a junior investigators research forum and will be focused on international collaboration in the following 5 areas:  1) Establishing an International entity to foster future meetings, data sharing, and innovative asthma research 2) Validating innovative disease mechanisms hypotheses, 3) Developing new technologies and therapies, 4) Organizing pilot studies of personalized severe asthma treatments, and 5) Engaging young investigators.

The program will be built around the selected abstracts which will be presented over a multi-day conference, one day virtual, other days in-person in May 2022. Attendees will be expected to attend both meeting dates.

Approximately 40 abstracts will be selected for oral presentation.

  1. For the virtual day, ~20 abstracts will be chosen for 15-minute presentation slots (8 minutes presentation, 7 minutes discussion).
  2. For the in-person days, ~20 abstracts will be chosen for 15-minute presentation slots (8 minutes presentation 7 minutes discussion)

Presentations may be in the form of a slide deck or a digital poster or both.

The abstract scoring criteria will be as follows:

  1. Novelty of the idea, preferably independent of targets and pathways currently funded by major industrial partners in drug development and extending beyond T2 mechanisms (20 points).
  2. Proposed or already applied use of collaborative data analysis across different international asthma networks (20 points).
  3. “Shovel-ready” programming approach to integrated application of big data networks for use in understanding asthma (10 points).
  4. Strength of the preliminary data (note that the ICAN abstract can expand upon, but not duplicate, data being presented at the 2022 ATS) (15 points).
  5. IP and potential translational relevance to personalized diagnosis or treatment (20 points).
  6. Potential for creating a reduction in the burden of asthma (15 points).
  7. Additionally, we will evaluate whether the abstract is related to one of the priorities in Table 1 of the asthma research prioritization exercise (please name which one)

Abstracts will be selected & notification will be sent by March 4, 2022. Registration will open on March 4, 2022.

All are welcome to submit, but we are particularly interested in hearing from junior and mid-career investigators who have innovative ideas in the beyond T2 asthma space, ideally supported by preliminary data or analyses; and we are also particularly interested in ideas  using international collaborative platforms.  Submissions from bioinformaticians, programmers and healthcare economists are welcome.

ATS interface. You may not present the same abstract and data you will have presented at ATS.  However, if your abstract is the “next step”, you may refer ICAN attendees to data you will be presenting at ATS as background.  For example, your data may have advanced between the time of the ATS abstract deadline and the ICAN deadline.  Also, if the innovation and value of your abstract were not well-recognized by the ATS abstract review committees (i.e., it is a brilliant, innovative, transformative idea that was only accepted for an ATS thematic poster session), you may submit it to ICAN for a higher profile presentation if you agree to withdraw the abstract from ATS if it is accepted for presentation at ICAN.

Abstract Format:

400 word maximum. A figure is allowed. Word or PDF acceptable. First author should be the presenting author.

 

Structure of the abstract

  1. Brief background presenting the overall unmet need
  2. Brief methods
  3. Preliminary data (if available)
  4. Proposed methodology for a collaborative study, if applicable
  5. Conclusion

Event details:

Where & When:

  • Virtual meeting – May 6, 2022  7:00-14:30 UCT-8
  • In person meeting – May 12 & 13 in San Francisco, CA. (May 12 18:00-20:00 local time; May 13 8:00-17:00 local time)

Event will take place at a hotel in San Francisco, CA. Additional details coming soon

What is the cost?

There is no cost associated with registration or the virtual portion of the meeting

For in-person meeting, lodging and select meals will be provided

Travel stipends will be available as follows: $500 for domestic/$1000 for EU/Africa $2000 for Asia Pacific

Frequently Asked Questions

I am a senior investigator with a novel idea. Can I submit an abstract?

All are welcome to submit, but we are particularly interested in hearing from junior and mid-career investigators who are not fully established and have innovative ideas in the beyond-T2 asthma space.

I am interested in attending this meeting even though I’ve not submitted an abstract. Can I attend?

Attendance to this meeting is by invitation only. Only those who have submitted an abstract and are selected to present will be invited to attend; Mentors/advisors of selected presenters may also be extended an invite, if listed as a mentor by the presenter, and if meeting resources allow. Other invited attendees are selected persons of skill and advisement strategic for the furthering of presenter’s ideas (i.e., an IP lawyer, a medical writer).

My abstract/my mentee’s abstract was not chosen for presentation but I am very interested in attending the meeting. Can I attend?

We appreciate your interest, but due to the design and funding of the event, attendance is limited to presenters, select presenter-mentors and a few invitees with niche skills for abstract advancement. We hope that in the years to come, we can expand this conference so there are opportunities for more people to engage.

The abstract of the junior investigator I suggested/mentor has been chosen. Can I attend the meeting?

During abstract submission, the submitter can name one academic mentor/advisor for an invitation-extension. If you were named as a mentor by a selected presenter and meeting resources allow, then you will receive an invitation to register on March 4, 2022.

I am a senior investigator whose suggested mentee has been chosen to present, so I am invited to attend. Will I receive a travel stipend?

Yes, travel stipends will be available for mentors of presenters for the meeting, as well as for presenters. If you do not wish to use the offered stipend, you can opt-out of claiming the stipend when registering and the allocated funds will be reserved for expanding the ICAN reach in the future.

My abstract was chosen for ICAN. Am I expected to attend both the virtual and in-person meetings?

Yes, if your abstract is chosen, you will be expected to attend both the virtual and in-person meetings.

Will there be a virtual option for the in-person meeting?

No, the in-person meeting will not have a virtual stream available; attendees are expected to attend in-person.

Is there a registration fee?

There is no registration fee for this event. There is also no fee associated with abstract submission. Lodging will be provided, as well as select meals during the conference. Travel stipends will be provided to offset travel costs

Will my flight be paid for?

Your flight will not directly be arranged or paid for by ICAN, but the stipends made available are intended to offset the cost of travel. Travel stipends are available as follows: $500 for domestic; $1,000 for EU/Africa; $2,000 for Asia Pacific.

Is lodging provided and paid for?

Yes, lodging will be covered for all ICAN Meeting attendees for the nights of…….March 4, 2022. Hotel details to come.

Can I stay at the venue after the ICAN meeting (for the ATS)?

es, you will be able to stay at the hotel ICAN is providing during ATS if you are attending both conferences. ICAN will cover lodging at this hotel for the nights of Wednesday, 5/11, Thursday, 5/12 and Friday, 5/13. Hotel details to come.

Will most people stay for ATS?

We expect that most people attending the meeting will stay for ATS.

My ATS abstract has been submitted. Can I also submit an abstract for ICAN?

You may not present the same abstract and data you will have presented at ATS. However, if your abstract is the “next step,” you may refer ICAN attendees to data you will be presenting at ATS as background. For example, your data may have advanced between the time of the ATS abstract deadline and the ICAN deadline. Also, if the innovation and value of your abstract were not well-recognized by the ATS abstract review committees (i.e., it is a brilliant, innovative, transformative idea that was only accepted for an ATS thematic poster session), you may submit it to ICAN for a higher profile presentation if you agree to withdraw the abstract from ATS.

When will registration open?

For those selected to present, and any selected corresponding mentors/advisors, registration will open on March 4, 2022.

Are there any safeguards against other attendees appropriating my ideas?

This meeting is a closed and confidential meeting; your presentation and ideas discussed at the meeting will not be disclosed outside of the meeting, comparable to the confidentiality of an NIH study section.

Will others have access to taking or using my data or ideas without my permission?

No.

If I have a novel idea and data, should I disclose it to my technology transfer office before presenting it?

It is always a good idea to do this before any public presentation. We encourage you to do this.